Holly Lee

728 total citations
37 papers, 187 citations indexed

About

Holly Lee is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Holly Lee has authored 37 papers receiving a total of 187 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Hematology, 20 papers in Molecular Biology and 20 papers in Oncology. Recurrent topics in Holly Lee's work include Multiple Myeloma Research and Treatments (21 papers), CAR-T cell therapy research (12 papers) and Amyloidosis: Diagnosis, Treatment, Outcomes (10 papers). Holly Lee is often cited by papers focused on Multiple Myeloma Research and Treatments (21 papers), CAR-T cell therapy research (12 papers) and Amyloidosis: Diagnosis, Treatment, Outcomes (10 papers). Holly Lee collaborates with scholars based in Canada, United States and Germany. Holly Lee's co-authors include Nizar J. Bahlis, Paola Neri, Noémie Leblay, Jason Tay, Elie Barakat, Sungwoo Ahn, Ranjan Maity, Peter Duggan, Christopher J. Doig and Víctor H. Jiménez‐Zepeda and has published in prestigious journals such as Blood, Nature Reviews Clinical Oncology and Hematology.

In The Last Decade

Holly Lee

32 papers receiving 185 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Holly Lee Canada 9 100 99 94 35 24 37 187
Britta Besemer Germany 11 197 2.0× 147 1.5× 160 1.7× 66 1.9× 26 1.1× 37 286
Louis Williams United States 9 110 1.1× 84 0.8× 67 0.7× 10 0.3× 29 1.2× 44 185
Kenji Nara Japan 5 121 1.2× 68 0.7× 102 1.1× 18 0.5× 18 0.8× 5 170
Luca Franceschini Italy 6 48 0.5× 71 0.7× 23 0.2× 9 0.3× 10 0.4× 15 144
Magdalena Sierra Spain 7 135 1.4× 126 1.3× 70 0.7× 3 0.1× 15 0.6× 14 236
Chiara Pavoni Italy 7 56 0.6× 31 0.3× 33 0.4× 11 0.3× 18 0.8× 18 117
Melinda Kedves Hungary 5 59 0.6× 32 0.3× 16 0.2× 18 0.5× 85 3.5× 6 238
Amy D Greenway United States 4 42 0.4× 26 0.3× 94 1.0× 5 0.1× 77 3.2× 9 165
Jack Godsell Australia 6 23 0.2× 40 0.4× 26 0.3× 18 0.5× 171 7.1× 9 231

Countries citing papers authored by Holly Lee

Since Specialization
Citations

This map shows the geographic impact of Holly Lee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Holly Lee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Holly Lee more than expected).

Fields of papers citing papers by Holly Lee

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Holly Lee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Holly Lee. The network helps show where Holly Lee may publish in the future.

Co-authorship network of co-authors of Holly Lee

This figure shows the co-authorship network connecting the top 25 collaborators of Holly Lee. A scholar is included among the top collaborators of Holly Lee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Holly Lee. Holly Lee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lee, Holly, Kim Cheema, Peter Duggan, et al.. (2025). Clinical and Pathological Characteristics of Non-AL Amyloidosis MGRS: A Single-Center Experience Over 10 Years. Canadian Journal of Kidney Health and Disease. 12. 1055274030–1055274030.
2.
Lee, Holly, Michael Durante, Sheri Skerget, et al.. (2024). Impact of soluble BCMA and non–T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma. Blood. 144(25). 2637–2651. 16 indexed citations
3.
Lee, Holly, Paola Neri, & Nizar J. Bahlis. (2024). Cereblon-Targeting Ligase Degraders in Myeloma. Hematology/Oncology Clinics of North America. 38(2). 305–319. 2 indexed citations
4.
Lee, Holly, Sungwoo Ahn, Mansour Poorebrahim, et al.. (2024). Tumor Intrinsic and Antigen-Independent Resistance Mechanisms to Bispecific T Cell Engagers in Multiple Myeloma. Blood. 144(Supplement 1). 1892–1892. 1 indexed citations
5.
Leblay, Noémie, Sungwoo Ahn, Holly Lee, et al.. (2024). Immune and Tumor Mediators of Resistance to Daratumumab-IMiDs Based Therapies in Relapsed Multiple Myeloma. Blood. 144(Supplement 1). 4642–4642.
6.
Lee, Holly, Mansour Poorebrahim, Sungwoo Ahn, et al.. (2024). NF-Kb Pathway Activation Driven By TRAF3 Loss Mediates Resistance to Anti-BCMA T-Cell Based Therapies in Multiple Myeloma. Blood. 144(Supplement 1). 591–591. 3 indexed citations
7.
Ahn, Sungwoo, Benjamin Diamond, Holly Lee, et al.. (2024). Timing Antigenic Escape in Multiple Myeloma Treated with T-Cell Redirecting Immunotherapies. Blood. 144(Supplement 1). 1899–1899.
8.
Lee, Holly, Mansour Poorebrahim, Sacha Benaoudia, et al.. (2024). BCMA Extracellular Domain Functional Hotspots and Resistance to Variable Anti-BCMA T Cell Engagers in Multiple Myeloma. Blood. 144(Supplement 1). 4651–4651. 1 indexed citations
9.
Neri, Paola, Noémie Leblay, Holly Lee, et al.. (2024). Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins. Nature Reviews Clinical Oncology. 21(8). 590–609. 9 indexed citations
10.
Levin, Daniel L., Holly Lee, Jason Tay, et al.. (2023). Daratumumab for the treatment of relapsed/refractory AL amyloidosis: experience from the amyloidosis Program of Calgary (APC). Leukemia & lymphoma. 65(3). 403–406.
11.
Leblay, Noémie, Sungwoo Ahn, Mansour Poorebrahim, et al.. (2023). Integrated epigenetic and transcriptional single-cell analysis of t(11;14) multiple myeloma and its BCL2 dependency. Blood. 143(1). 42–56. 14 indexed citations
12.
Poorebrahim, Mansour, Holly Lee, Sacha Benaoudia, et al.. (2023). Bclxl Prevents Progressive Exhaustion in BCMA CAR T Cells with Maintenance of High TCF1 Expressing T Cells. Blood. 142(Supplement 1). 454–454. 2 indexed citations
13.
14.
Jiménez‐Zepeda, Víctor H., Holly Lee, Jason Tay, et al.. (2021). N-Terminal pro-brain natriuretic peptide (NTproBNP) in patients with symptomatic multiple myeloma: report from a single institution. Annals of Hematology. 100(10). 2521–2527. 3 indexed citations
15.
Jiménez‐Zepeda, Víctor H., Holly Lee, Nowell M. Fine, et al.. (2021). Cyclophosphamide, Bortezomib and Methylprednisolone (CyBorMe) for the Treatment of AL Amyloidosis: Initial Experience From a Single Center. Indian Journal of Hematology and Blood Transfusion. 37(4). 675–678. 1 indexed citations
16.
Lee, Holly, et al.. (2021). Monoclonal Gammopathy of Undetermined Significance Clinic during the Coronavirus Disease-19 Pandemic: Caring for the Vulnerable in an Academic Medical Center. Revista de investigaci�n Cl�nica. 73(4). 259–264. 2 indexed citations
17.
Friedrich, Mirco, Paola Neri, Noémie Leblay, et al.. (2021). Mapping the Multiple Myeloma T Cell Landscape By Immunotherapeutic Perturbation Reveals Mechanism and Determinants of Response to Bispecific T Cell Engagers. Blood. 138(Supplement 1). 731–731. 1 indexed citations
18.
Lee, Holly, et al.. (2019). Bortezomib maintenance for the treatment of Monoclonal Gammopathy of Renal Significance. Mediterranean Journal of Hematology and Infectious Diseases. 11(1). e2019007–e2019007. 5 indexed citations
19.
Solverson, Kevin, Holly Lee, & Christopher J. Doig. (2018). Intentional overdose of liraglutide in a non-diabetic patient causing severe hypoglycemia. Canadian Journal of Emergency Medicine. 20(S2). S61–S63. 12 indexed citations
20.
Lee, Holly, Peter Duggan, Ahsan Chaudhry, et al.. (2017). Early Relapse for Multiple Myeloma Patients Undergoing Single Autologous Stem Cell Therapy: A Single-center Experience. Clinical Lymphoma Myeloma & Leukemia. 18(1). e69–e75. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Britta Besemer Breakdown of academic impact, for papers by Louis Williams Breakdown of academic impact, for papers by Kenji Nara Breakdown of academic impact, for papers by Luca Franceschini Breakdown of academic impact, for papers by Magdalena Sierra Breakdown of academic impact, for papers by Chiara Pavoni Breakdown of academic impact, for papers by Melinda Kedves Breakdown of academic impact, for papers by Amy D Greenway Breakdown of academic impact, for papers by Jack Godsell
Rankless by CCL
2026